IMAC HOLDINGS INC. - COMMON STOCK

Ignite Proteomics to Present Data on MHC-II as a Predictor of Pembrolizumab Response at NCCN Annual Conference

24 Feb 2025 07:15:00 By Nasdaq GlobeNewswire

Ignite Proteomics Completes Acquisition of PLA Code 0249U for Its Advanced Proteomic Breast Cancer Assay

19 Feb 2025 08:15:00 By Nasdaq GlobeNewswire

Ignite Proteomics Announces Publication of Study Demonstrating Superiority of Protein Activation Analysis in Predicting Breast Cancer Therapy Response

10 Feb 2025 08:15:00 By Nasdaq GlobeNewswire

IMAC Holdings Introduces Ignite Proteomics: A New Standard for Matching Patients with the Right Cancer Therapies

27 Jan 2025 15:10:00 By Nasdaq GlobeNewswire

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

22 Nov 2024 16:15:00 By Nasdaq GlobeNewswire

IMAC Holdings Granted Extension by Nasdaq to Regain Compliance with Listing Rule 5250(c)(1)

14 Nov 2024 08:10:00 By Nasdaq GlobeNewswire

IMAC Holdings Inc. Launches Subsidiary Ignite Proteomics and Announces Groundbreaking Precision Oncology Case Study Utilizing RPPA Technology

19 Sep 2024 09:00:00 By Nasdaq GlobeNewswire

IMAC Holdings receives notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

23 Aug 2024 16:20:00 By Nasdaq GlobeNewswire

IMAC Holdings, Inc. Appoints Dr. Matthew Schwartz and Dr. Peter Beitsch to Board of Directors

11 Jul 2024 08:21:00 By Nasdaq GlobeNewswire

IMAC Holdings Announces Leadership Succession

24 May 2024 08:00:00 By Nasdaq GlobeNewswire

IMAC Holdings Acquires Assets of Theralink to Continue Precision Medicine Business

07 May 2024 07:30:00 By Nasdaq GlobeNewswire